Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Liver Neoplasms 1Hematologic Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Brain Neoplasms 1

Interventions

durvalumab 7Bevacizumab 6tremelimumab 3Nivolumab 3lenvatinib 2fludarabine 2Cyclophosphamide 2zimberelimab 1toripalimab 1ropidoxuridine 1relatlimab 1pembrolizumab 1fludarabine phosphate 1atezolizumab 1X-Rays 1Technetium Tc 99m Aggregated Albumin 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radionuclide Imaging 1Platinum 1Photons 1Paclitaxel 1Observation 1Long-Term Potentiation 1Lidocaine 1Immunotherapy 1Immunoglobulin G 1IMC-001 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Liver Neoplasms × ropidoxuridine × Clear all
NCT02381561 2026-04-13

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy

National Cancer Institute (NCI)

Phase 1 Active not recruiting
19 enrolled
Gastrointestinal

Colonic Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡